Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NX-019 in advanced EGFR-mutant cancer
NCT05514496Phase 1Active, not recruiting
- Sponsor
- Nalo Therapeutics
- Start
- Oct 2022
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of nx-019 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Nalo Therapeutics. Primary endpoints: Incidence of Treatment-emergent Adverse Events up to 4.5 years, Incidence of Adverse Events of Special Interest up to 4.5 years and 2 more. Started Oct 2022; status: active, not recruiting.
02
Drugs
nx-019
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05514496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05514496.